AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.

Authors :: Wang Q
Gao S
Shou Y
Jia Y
Wei Z
Liu Y
Shi J
Miao D
Miao Q
Zhao C
Liu C
Yang H
Xu T
Zhang X
Source :: International journal of biological sciences [Int J Biol Sci] 2023 Feb 13; Vol. 19 (4), pp. 1266-1283. Date of Electronic Publication: 2023 Feb 13 (Print Publication: 2023).
Publication Year :: 2023
Abstract: Renal cell carcinoma (RCC) is a serious threat to people's health due to its rapid progression, and patients easily develop resistance to targeted therapy. The absent in melanoma 2 (AIM2) is a receptor protein that has recently been proposed to play an important role in various diseases. In this study, AIM2 was identified as a new biomarker of RCC and promoted RCC progression and sunitinib resistance in an inflammasome-independent manner. Mechanistically, AIM2 promoted FOXO3a phosphorylation and proteasome degradation, thereby reducing its transcriptional effect on ACSL4 and inhibiting ferroptosis. In summary, AIM2 promoted RCC progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis, which could provide new ideas and therapeutic targets for RCC diagnosis and treatment.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)

Subjects :: Humans
Sunitinib pharmacology
Sunitinib therapeutic use
Cell Line, Tumor
Drug Resistance, Neoplasm genetics
DNA-Binding Proteins
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell genetics
Carcinoma, Renal Cell metabolism
Kidney Neoplasms drug therapy
Kidney Neoplasms genetics
Kidney Neoplasms metabolism
Ferroptosis genetics
Melanoma

Full Text Access

Tools